EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses

Apirath Wangteeraprasert, Sutatip Pongcharoen, Jatuporn Ngoenkam, Supawadee Makanut iD

mSphere · 2025

DOI: 10.1128/msphere.00722-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, 2025. Verfasst von Apirath Wangteeraprasert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand. Hauptthemen laut MEDLINE: Immunization, Secondary, COVID-19, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS, Naresuan University, Thailand Science Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present study investigated T and B cell responses following a second heterologous booster dose of BNT162b2 administered after a two-dose CoronaVac regimen for coronavirus disease 2019 (COVID-19) vaccination in 15 healthcare workers. Blood samples were collected 4 weeks after the first booster and at both 4 and 24 weeks after the second BNT162b2 booster. Interferon-γ-secreting CD4+ and CD8+ T cells were detectable 4 weeks after the first booster, whereas only CD4+ T cells remained detectable at both 4 and 24 weeks after the second booster. Seven of the 15 participants (46.7%) were diagnosed with COVID-19 approximately 16 weeks after receiving the second booster. These individuals exhibited significantly higher frequencies of CD4+ T cells at 24 weeks post-booster than at 4 weeks post-booster. In contrast, the non-COVID-19 group exhibited significantly higher CD4+ T cell responses 4 weeks after the second booster. Memory B cells were detected at low frequencies at all three time points. IgG antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein were detectable at all three time points, with a significant decline observed 24 weeks after the second booster. Overall, CD4+ T and B cell responses induced by a heterologous second booster dose of BNT162b2 following a primary two-dose CoronaVac regimen were rapidly elicited and sustained for at least 6 months. IMPORTANCE There is limited evidence regarding T and B cell responses following a primary COVID-19 vaccination series with CoronaVac and two heterologous BNT162b2 booster doses. This study investigated the longitudinal T and B cell responses induced by a second heterologous BNT162b2 booster following a primary two-dose CoronaVac COVID-19 vaccination regimen. These results demonstrate that CD4+ T cells induced by the second heterologous BNT162b2 booster play a key role in protection against SARS-CoV-2 infection and progression to severe disease. This study suggests the need for the future consideration of repeated emergency vaccine-boosting strategies in response to emerging viral infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunization, SecondaryCOVID-19SARS-CoV-2COVID-19 VaccinesB-LymphocytesHumansBNT162 VaccineMaleFemaleAdultCD4-Positive T-LymphocytesAntibodies, ViralMiddle AgedCD8-Positive T-LymphocytesVaccinationImmunoglobulin GHealth PersonnelInterferon-gammaVaccines, Inactivated

Stichwörter der Autor:innen

CD4+ T cellCD8+ T cellCOVID-19 vaccinesmemory B cellmemory T cell

Substanzen

BNT162 VaccineCOVID-19 VaccinesAntibodies, ViralImmunoglobulin GInterferon-gammasinovac COVID-19 vaccineVaccines, Inactivated

Autor:innen und Institutionen

  • Division of Immunology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand.
  • Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.
  • Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand.

ORCID-Profile: Supawadee Makanut

Förderung

  • NIMHD NIH HHS
  • Naresuan University
  • Thailand Science Research and Innovation

Zitieren

APA

Wangteeraprasert, A., Pongcharoen, S., Ngoenkam, J., & Makanut, S. (2025). T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses. mSphere. https://doi.org/10.1128/msphere.00722-25

Vancouver

Wangteeraprasert A, Pongcharoen S, Ngoenkam J, Makanut S. T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses. mSphere. 2025. doi:10.1128/msphere.00722-25

BibTeX
@article{Wangteeraprasert2025,
  author = {Wangteeraprasert, Apirath and Pongcharoen, Sutatip and Ngoenkam, Jatuporn and Makanut, Supawadee},
  title = {T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses},
  journal = {mSphere},
  year = {2025},
  doi = {10.1128/msphere.00722-25}
}
Kostenlos starten →